Organ-on-a-chip Market Research Report Information By Organ Type (Lung-on-Chip, Heart-on-Chip, Liver-on-Chip, Intestine-on-Chip, Kidney-on-Chip, Human-on-Chip), By Application (Drug Discovery, Toxicology Research, Others) and By End-User (Pharmaceutical Companies, Research Organizations, Others) – Forecast to 2032

Organ on chip Market Summary

As per MRFR Analysis, the Global Organ-On-a-Chip Market is projected to reach USD 0.23 Billion by 2032, growing at a CAGR of 11.7% from 2023 to 2032. Organs-on-chips (OOCs) are innovative devices that replicate human organ functions using live human cells in a controlled environment. The market is currently limited due to the ongoing research and development phase, but increasing collaborations between pharmaceutical companies and universities, along with advancements in organ-specific models, are expected to drive growth. Key factors influencing market expansion include reduced drug development costs and increased funding from various entities. The market is characterized by significant investments in R&D and a growing demand for drug screening solutions.

Key Market Trends & Highlights

The Organ-On-a-Chip market is witnessing significant growth driven by technological advancements and strategic collaborations.

• Market size expected to reach USD 0.23 Billion by 2032; CAGR of 11.7% during 2023-2032.
• Lung-on-Chip holds approximately 20% market share as of 2018; largest segment in the market.
• Major companies like CN Bio secured $21 million in funding for OOC development in April 2024.
• Increasing government initiatives and funding for OOC R&D, exemplified by InSphero's $10 million grant in 2018.

Market Size & Forecast

Market Size: USD 0.23 Billion by 2032

CAGR: 11.7% (2023-2032)

Largest Regional Market: Americas

Fastest Growing Region: Asia-Pacific

Major Players

CN Bio Innovations Limited (UK), Emulate, Inc. (US), TissUse GmbH (Germany), MIMETAS BV (Netherlands), Hµrel Corporation, Nortis, Inc. (US), InSphero (Switzerland), TARA Biosystems, Inc. (US), Axosim (US), Organovo Holdings Inc. (US), BioIVT (US), HemoShear Therapeutics, LLC (US)

Organs-on-chips (OOCs) are small plastic devices with biocompatible microfluidic chambers, which contain multiple live human cells in a 3D culture that simulate vital physiological functions of body organs. These cells are placed in an environment that artificially replicates aspects of the human body, such as morphology, movement, flow, electrical stimuli, and liquid gradients.

There has been an increase in the number of collaborative sales agreements between pharmaceutical companies and university spin-offs and the entry of new advanced models of OOCs into the market. The anticipated launch of advanced organ-specific models and human-on-chip models is expected to increase the growth rate of this Organ-On-a-Chip market in the future further.

The small size of the market is mainly because OOCs have not yet been fully commercialized. They are still in the research and development phase and are being used by a limited number of end-users.

There has been a notable rise in the prevalence of joint sales agreements between pharmaceutical corporations and university spin-offs, accompanied by the introduction of novel advanced models of organ-on-a-chip (OOC) systems onto the market. The future growth rate of the Organ-On-a-Chip market is likely to be further increased by the forthcoming development of enhanced organ-specific models and human-on-chip models. 

Furthermore, the market growth is expected to be driven by enhanced drug screening procedures, which have led to increased research and development activities by key industry players. Additionally, strategic efforts and developments in technology are also projected to contribute to the growth of the market in the forecast future.

The market growth is primarily influenced by two key factors: the significant cost reduction in drug development achieved via the use of organ-on-a-chip (OOC) models, and the availability of funds from both government and non-government groups. The projected growth at a high compound annual growth rate (CAGR) may be attributed to the growing number of collaborative sales agreements between pharmaceutical firms and university spin-offs, as well as the introduction of new sophisticated models of organ-on-a-chip (OOC) technology in the market. 

The future growth rate of the Organ On a Chip market is likely to be further enhanced by the forthcoming introduction of sophisticated organ-specific models and human-on-chip models.

In June 2024: Emulate, Inc. launched a new version of their organ-on-a-chip platform designed to better simulate human liver function. This upgrade is expected to improve the accuracy of drug metabolism studies.

In April 2024, CN Bio secured $21 million in the first close of their Series B investment round, with Bayland Capital and CN Innovations Holdings Ltd contributing significantly.

Organ-On-a-Chip Market Trends

The ability of OOC models to reduce drug development costs drastically and grants by government and non-government entities are the major factors influencing the market growth. It is expected to rise at this high CAGR due to an increase in the number of collaborative sales agreements between the pharmaceutical companies and university spin-offs and the entry of new advanced models of OOCs into the market. The anticipated launch of advanced organ-specific models and human-on-chip models is expected to further increase the growth rate of this Organ On a Chip market in the future. Grants by government and non-government entities have been the key drivers for the global OOC industry to date. The ability of OOC models to cut drug development costs drastically will be a key market driver in the future.

Moreover, improved drug screening methodologies increased R&D by major players, strategic initiatives and increasing technological advancements are also anticipated to fuel the market growth during the forecast period.

Drivers

• Increasing investment by major companies in organ-on-a-chip research & development (r&d)

• The growing demand for drug screening with organs-on-a-chips

• Increasing focus of organ-on-chips companies on an integrated approach, OOCs for human disease models, personalized drug tests, and regulatory status of tests using MOOCs

• Increasing government initiatives and government funding for R&D of OOCs: Major companies such as Mimetas and InSphero have been collaborating with the government agencies and universities in the US and Europe for the development of novel and effective OOCs. For instance, in 2018, InSphero received USD 10 million government funding for the R&D of said OOC models.

Restraints

• Stringent government regulations for drug approvals
• The complexity of OOC models

Organ-On-a-Chip Market Segment Insights

Organ-on-a-chip Organ Type Insights

• Lung-on-Chip: It is the largest segment in the Organ On a Chip market and had a share of approximately 20% in 2018. Lung on a chip is a complex three-dimensional model of a living, breathing human lung on a microchip.

• Heart-on-Chip: It is a device that is used to produce cardiac tissues in three-dimension models. This device is used to study cardiac drug development and cardiotoxicity testing for personalized medicine and damaged heart tissue regeneration.

• Liver-on-Chip: This chip generates biochemical and metabolic information and shows the functioning of the liver. Fluorescent biosensor cells in the chip show changes in liver cell functions including cell death or damage to free radicals. The significant applications of liver on chips are to test general toxicity, mechanistic toxicity, and nutrient metabolism.

• Intestine-on-Chip: These chips are used to study intestinal physiology and pathophysiology of human intestines. It is also used as a research tool for applications such as studies of metabolism, nutrition, infection, and drug pharmacokinetics, as well as personalized medicine.

• Kidney-on-Chip: Kidney on chips constitute organ-chips, cells, and reagents. These chips are used in testing general toxicity, mechanistic toxicity, and drug transportation in kidneys. 

• Skin-on-Chip: These chips are used in stimulating inflammation, edema, and drug-based skin disease treatments. Skin on chips is used to culture skin tissues within a microfluidic system that controls many physical and biochemical parameters of the human skin.

• Blood-Brain Barrier-on-Chip: These chips are used in maintaining brain homeostasis, immunocytochemistry for analyzing cell morphology and protein marker expression, permeability assay, and calcium imaging for studying neuronal functioning of the brain.

• Human-on-Chip: These are microfluidic devices that are lined with living human cells and are used for drug development, disease modeling, and personalized medicine. These chips are also used to predict human pharmacokinetic and pharmacodynamic responses of drugs on the human body.

Organ-on-a-chip Application Insights

• Drug Discovery: The largest segment in the Organ on a Chip market, owing to a large number of pharmaceutical companies are focusing on drug testing through organ-on-chip models.

• Toxicology Research: It is the second-largest segment in the Organ on a Chip market owing to major universities and research centers are focusing on the application of OOCs in drug toxicology testing, which is a much more advanced model compared to other drug toxicology testing methods.

• Others: Other applications of OOCs include the food & beverage and cosmetic industries

Organ-on-a-chip End-User Insights

• Pharmaceutical Companies: It is the largest segment owing to the rise in the number of pharmaceutical companies using OOCs for their r&d, drug toxicity, and efficacy testing.

• Research Organizations: It is the second-largest segment in the Organ on a Chip market owing to major universities, research organizations, non-profit research centers that are focusing on the application of OOCs in drug toxicology testing. For instance, the Wyss Institute received almost USD 5.6 million in grant money from the US FDA to use its organ-on-chip technology to test humans in 2017.

• Others: Includes small clinics and institutes and individual researchers that are working on r&d of OOCs

Organ-On-a-Chip Regional Insights

Americas: The largest regional Organ on a Chip market. Owing to the availability of a wide range of products and services offered by major players, including customized designing of new chips with specific organ arrangement and increase in toxicological testing of chemicals on the different types of organ cells.

Europe: It is the second-largest market and expected to grow at a steady rate during the forecast period. Establishment of major OOC providers in five countries of the European Union (EU), namely the UK, Germany, France, Italy, and Spain; government initiatives and government funding to research institutes; collaborations among companies and universities to develop innovative OOCs, and a well-developed healthcare infrastructure expected to drive the market growth.

Asia-Pacific: The fastest-growing regional Organ on a Chip market. Furthermore, the region has a supportive regulatory framework for the approval of OOCs in South Korea, Australia, Japan, and China. This factor, along with a high prevalence of chronic diseases, will drive the market during the forecast period.

Middle East & Africa: The Middle Eastern Organ on a Chip market is expected to show more growth as compared to the African market, owing to the presence of developed countries such as Saudi Arabia and Oman in the region.

Organ-on-a-chip Industry Developments

In January 2024,Emulate Announced partnership with Pfizer to develop OoC models for drug discovery and safety testing.In September 2023, CN Bio, a prominent company specializing in Organ-on-a-Chip (OOC) technology for designing and producing microphysiological systems (MPS) with single and multiple organs, entered into a strategic partnership with LifeNet Health LifeSciences, also known as "LifeNet Health." LifeNet Health is a non-profit organization recognized globally for its expertise in all-human research solutions. The purpose of this collaboration is to provide CN Bio's PhysioMimix® OOC series of MPS with validated primary human cells. 

The agreement entails the inclusion of LifeNet Health's hepatic cells, which have been validated for high quality and MPS, in CN Bio's Non-Alcoholic Steatohepatitis (NASH) 'in-a-box' kit. Alternatively, customers can directly obtain these cells from LifeNet Health. This collaboration offers customers a simplified solution to replicate the advanced in vitro liver models developed by the Company and enhance the success of their assays.

In November 2023,Emulate Inc. announces the launch of its new Liver-on-a-Chip platform, a microfluidic device that can be used to model liver function in vitro. The Liver-on-a-Chip platform is designed to provide researchers with a more accurate and reliable way to study liver diseases and develop new treatments.

InSphero AG announces the launch of its new Skin-on-a-Chip platform, a microfluidic device that can be used to model skin function in vitro. The Skin-on-a-Chip platform is designed to provide researchers with a more accurate and reliable way to study skin diseases and develop new treatments.

In November 2023,Organovo Inc. announces the launch of its new Ex Vivo Kidney platform, a bioengineered kidney that can be used to model kidney function in vivo. The Ex Vivo Kidney platform is designed to provide researchers with a more accurate and reliable way to study kidney diseases and develop new treatments.

In April 2023,The development of a multi-organ chip on-a-chip, utilizing 3D cell printing technology, has been successfully accomplished by a team of researchers from Pohang University of Science and Technology (POSTECH) in South Korea and Eunpyeong St. Mary's Hospital of the Catholic University of Korea. This innovative chip aims to closely mimic the pathological conditions associated with type 2 diabetes (T2D). In order to simulate the pathogenic characteristics of diabetes and its consequences, the study team produced bioinks sourced from the pancreas, adipose tissue, and liver, which exhibit significant associations with Type 2 Diabetes (T2D). 

Subsequently, the researchers utilized 3D cell printing techniques to fabricate a multi-organ chip on-a-chip platform, strategically designed to accurately replicate the pathological features associated with Type 2 Diabetes (T2D). 

Organ-On-a-Chip Market Key Players

• CN Bio Innovations Limited (UK)
• Emulate, Inc. (US)
• TissUse GmbH (Germany)
• MIMETAS BV (Netherlands)
• Hµrel Corporation
• Nortis, Inc. (US)
• InSphero (Switzerland)
• TARA Biosystems, Inc. (US)
• Axosim (US)
• Organovo Holdings Inc. (US)
• BioIVT (US)
• HemoShear Therapeutics, LLC (US)

Report Attribute/Metric	Details
Market Size	USD 0.23 Billion
CAGR	11.7% (2023- 2032)
Base Year	2022
Forecast Period	2023-2032
Historical Data	2021
Forecast Units	Value (USD Million)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	Organ Type, Application and End-User
Geographies Covered	North America, Europe, Asia-Pacific, and Rest of the World (RoW)
Key Vendors	CN Bio Innovations Limited (UK), Emulate, Inc. (US), TissUse GmbH (Germany), MIMETAS BV (Netherlands), Hµrel Corporation, Nortis, Inc. (US), InSphero (Switzerland), TARA Biosystems, Inc. (US), Axosim (US), Organovo Holdings Inc. (US), BioIVT (US), HemoShear Therapeutics, LLC (US)
Key Market Opportunities	Ability of OOC models to reduce drug development costs drastically and grants by government and non-government entities
Key Market Drivers	·  Increasing investment by major companies in organ-on-a-chip research & development·  The growing demand for drug screening with organs-on-a-chips